MedTrace Logo

A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV

NCT05904470 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 275

Last updated 2025-10-21

Study results available
· View outcomes & findings →

Summary

This is an open-label trial to evaluate safety and efficacy of treatment with BEM + RZR in subjects with chronic HCV infection.

Conditions

  • Chronic Hepatitis C Virus
  • Hepatitis C, Chronic
  • Hepatitis C
  • Hepatic Cirrhosis
  • HCV

Interventions

DRUG

Bemnifosbuvir

550 mg administered orally once a day (QD) for 8 weeks

DRUG

Ruzasvir

180 mg administered orally once a day (QD) for 8 weeks

Sponsors & Collaborators

  • Atea Pharmaceuticals, Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-30
Primary Completion
2024-12-09
Completion
2025-01-28
FDA Drug
Yes

Countries

  • United States
  • Brazil
  • Canada
  • India
  • Mauritius
  • Moldova
  • Pakistan
  • Philippines
  • Romania
  • South Africa
  • South Korea
  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05904470 on ClinicalTrials.gov